Cargando…
Novel candidate drugs in anti-tumor necrosis factor refractory Crohn’s diseases: in silico study for drug repositioning
Biologicals like anti-tumor necrosis factor (TNF) therapy for Crohn’s disease (CD) are safe and effective but there is a significant rate of primary and secondary nonresponse in the patients. In this study, we applied a computational approach to discover novel drug therapies for anti-TNF refractory...
Autores principales: | Kwak, Min Seob, Lee, Hun Hee, Cha, Jae Myung, Shin, Hyun Phil, Jeon, Jung Won, Yoon, Jin Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330029/ https://www.ncbi.nlm.nih.gov/pubmed/32612148 http://dx.doi.org/10.1038/s41598-020-67801-0 |
Ejemplares similares
-
Single-Cell Network-Based Drug Repositioning for Discovery of Therapies against Anti-Tumour Necrosis Factor-Resistant Crohn’s Disease
por: Kwak, Min Seob, et al.
Publicado: (2023) -
Development of a Novel Metagenomic Biomarker for Prediction of Upper Gastrointestinal Tract Involvement in Patients With Crohn’s Disease
por: Kwak, Min Seob, et al.
Publicado: (2020) -
Practical strategy for optimizing the timing of anti-tumor necrosis factor-α therapy in Crohn disease: A nationwide population-based study
por: Kwak, Min Seob, et al.
Publicado: (2020) -
Uncovering Novel Pre-Treatment Molecular Biomarkers for Anti-TNF Therapeutic Response in Patients with Crohn’s Disease
por: Kwak, Min Seob, et al.
Publicado: (2022) -
Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer
por: Kim, In-Wha, et al.
Publicado: (2019)